ISSN: 7027-2221

Keywords : Curcumin

Erectile Dysfunction in Diabetic Patients in the Holy Kerbala/Iraq in 2018

karbala journal of pharmaceutical sciences, Volume 9, Issue 15, Pages 1-10

Erectile dysfunction affects more than 50% of diabetic patients and results in miserable
couple’s life, especially for young adults. Possible predictors are proper therapy and
patient’s compliance with treatment, in addition to the warning signs and symptoms of
sensory neuron and motor deficits. Therefore, this study was conducted to determine the
prevalence of Erectile dysfunction and its predictors among diabetic patients in Kerbala.
Material and methods
The study included a convenient sample of 61 patients with diabetes mellitus type I and II.
They were chosen through a systematic sampling among patients at the diabetes mellitus
clinic at Al Hussein Teaching Hospital in Holy Kerbala /Iraq in 2018. All participants
were interviewed using standard questionnaire. Analysis of data used descriptive and
analytic tools including t-test, chi-square test, logistic regression and structural Equation
modeling through the statistical Package of social sciences and Amos and Excel software
at a significance level of


diabetes mellitus
erectile dysfunction
Autonomic changes
sensory and motor changes
glycemic control.

Response to Helicobacter pylori Eradication Triple Therapy in Peptic Ulcer Disease Patients on Curcumin Supplement According to different ABO Phenotypes

karbala journal of pharmaceutical sciences, Volume 9, Issue 15, Pages 11-31

Background: Helicobacter pylori infection is one of the most predominant causes of peptic
ulcer disease. There was a correlation between H. pylori infection and ABO phenotypes in peptic
ulcer disease patients. Curcumin has anti- H. pylori effect due to its anti-oxidant, antiinflammatory,
anti- microbial, and anti-carcinogenic effect.
Patients and Methods: This study is a prospective randomized interventional open-label study
which designed to show the potential benefit of adjuvant curcumin therapy in peptic ulcer
disease Iraqi patients with different ABO phenotypes. The patients were allocated into two
groups, group (1) treated with standard triple H. pylori eradication, and group (2) treated with
curcumin capsules as adjuvant with the standard triple therapy for two weeks. The ABO
phenotypes detected by Anti ABO and Anti-D monoclonal kit and the H. pylori infection was
detected at the baseline and after 6 weeks of completion treatment course.
Results: highly significant improvement in H. pylori eradication after addition adjuvant curcumin
to standard H. pylori eradication triple therapy compared to standard triple therapy alone(P<0.01)
for patients holding blood group AB phenotypes ( P<0.01) and significant improvement for
patients holding blood group O phenotypes( P<0.05) reach up to (100 %) after 6 weeks from the
intervention starting point. Besides, there was improvement in H. pylori eradication for patients
holding blood group A and B phenotypes with adjuvant curcumin therapy, though no significant
(P>0.05). This study showed no significant difference in BMI among ABO phenotypes (A,B,
AB, and O) for both groups 1 and 2 patients after 6 weeks from the intervention starting